NeoStem, Inc. Receives Notification of Second Year Grant Award for Phase 2 Clinical Study of VSEL Technology in Periodontitis
9/13/2013 9:20:01 AM
NEW YORK, Sept. 13, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy industry, today announced that it has been awarded funds for the second year of a two year grant totaling $1,221,854 for "Repair of Bone Defects with Human Autologous Pluripotent Very Small Embryonic-Like Stem Cells (VSEL)," from the National Institute of Dental & Craniofacial Research ("NIDCR"), a division of the National Institutes of Health ("NIH"). This peer reviewed grant is to support a Phase 2 investigation and first approved NIH clinical study of VSELsTM in humans. Enrollment for this study is expected to begin in 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by